Share This Author
Update of systemic immunotherapy for advanced urothelial carcinoma.
Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer
- K. Bakirhan, J. Sharma, R. Perez-soler, H. Cheng
- MedicineCurrent Treatment Options in Oncology
- 4 March 2016
Opinion statementLung cancer is the leading cause of cancer-related deaths worldwide. In the USA, ≈60 % of lung cancer cases are diagnosed in elderly patients (≥65 years of age). However, elderly…
Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.
The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy
- J. Sharma, E. Shum, Vincent Chau, Daniel Paucar, H. Cheng, B. Halmos
- Medicine, BiologyRespiration
- 29 November 2016
Prior to the last decade, treatment for lung cancer was differentiated only by the main histological groups of small cell lung cancer (SCLC) and NSCLC. However, it is now known that differences in…
Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population
Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies
- D. A. Adrianzen Herrera, Shlomit Goldberg-Stein, A. Sankin, Judy Sarungbam, J. Sharma, B. Gartrell
- MedicineFront. Oncol.
- 30 April 2018
A patient with coexistent bone metastasis from multiple myeloma and prostate adenocarcinoma who exhibited synchronous bone involvement of both histologies within the same bone lesion is presented, a rare phenomenon that has not been previously reported and led to atypical radiographic findings.
Increased length of stay and cost of hospitalization in patients receiving inpatient radiation therapy.
Determining length of stay (LOS) and the attributable costs for hospital admissions are of critical importance for patients, providers, payers, and hospital management.
Emerging treatment for ALK-positive lung cancer
- J. Sharma, V. Pareek, Huijie Liu, H. Cheng
- Biology, MedicineExpert opinion on emerging drugs
- 2 April 2016
This review will discuss emerging treatment options in ALK-positive advanced NSCLC and strategies to overcome resistance mechanisms, including newer generation of ALK inhibitors, Hsp90 inhibitors and immunotherapy.
Kidney cancer mortality disparities among Hispanics in the US.
Genomic profiling of prostate cancer at a diverse academic center.
Clinical trial data demonstrates that prostate cancer patients with metastatic prostate cancer may harbor alterations in DNA damage repair (DDR) genes, and these genes have an important role in cell reprograming.